OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS
|
|
- Annabel Fields
- 7 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 34, No. 1, by the American College of Cardiology ISSN /99/$20.00 Published by Elsevier Science Inc. PII S (99)00145-X Pravastatin Prevents Clinical Events in Revascularized Patients With Average Cholesterol Concentrations Greg C. Flaker, MD, FACC,* J. Wayne Warnica, MD, FACC, Frank M. Sacks, MD, Lemuel A. Moyé, MD, PHD, Barry R. Davis, MD, PHD, Jean L. Rouleau, MD, Richard R. Webel, MD,* Marc A. Pfeffer, MD, PHD, Eugene Braunwald, MD, for the Cholesterol and Recurrent Events CARE Investigators** Columbia, Missouri; Calgary, Alberta, Canada; Houston, Texas; Boston, Massachusetts; Montreal, Quebec OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS This analysis was carried out to determine if revascularized patients derive benefit from the 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin. The HMG-CoA reductase inhibitors result in substantial reductions in serum cholesterol and stabilization of atherosclerotic plaques in patients with coronary artery disease. Pravastatin was found to reduce clinical cardiovascular events in the Cholesterol and Recurrent Events (CARE) trial consisting of 4,159 patients with a documented myocardial infarction and an average cholesterol level (mean 209 mg/dl and all 240 mg/dl). A total of 2,245 patients underwent coronary revascularization before randomization including 1,154 patients with percutaneous transluminal coronary angioplasty (PTCA) alone, 876 patients with coronary artery bypass graft (CABG) alone, and 215 patients with both procedures. Clinical events in revascularized patients were compared between patients on placebo and on pravastatin. In the 2,245 patients who had undergone revascularization, the primary endpoint of coronary heart disease death or nonfatal myocardial infarction () was reduced by 4.1% with pravastatin (relative risk [RR] reduction 36%, 95% confidence interval [CI] 17 to 51, p 0.001). Fatal or nonfatal was reduced by 3.3% (RR reduction 39%, 95% CI 16 to 55, p 0.002), postrandomization repeat revascularization was reduced by 2.6% (RR reduction 18%, 95% CI 1 to 33, p 0.068) and stroke was reduced by 1.5% (RR reduction 39%, 95% CI 3 to 62, p 0.037) with pravastatin. Pravastatin was beneficial in both the 1,154 PTCA patients and in the 1,091 CABG patients who had undergone revascularization before randomization. Pravastatin reduced clinical events in revascularized postinfarction patients with average cholesterol levels. This therapy was well tolerated and its use should be considered in most patients following coronary revascularization. (J Am Coll Cardiol 1999;34:106 12) 1999 by the American College of Cardiology Percutaneous cardiac interventions and bypass surgery play a central role in the management of patients with ischemic heart disease. In the U.S. in 1995, approximately 410,000 percutaneous coronary revascularization procedures and 590,000 coronary bypass procedures were performed (1). Although these procedures frequently relieve symptoms, From the *University of Missouri, Columbia, Missouri; Foothills Hospital, Calgary, Alberta, Canada; University of Texas School of Public Health, Houston, Texas; Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts; and Montreal Heart Institute, Montreal, Quebec, Canada. **A complete list of Care Investigators appears in reference 5. The Cholesterol and Recurrent Events trial was funded by an investigator-initiated grant from the Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey. Manuscript received October 26, 1998; revised manuscript received February 2, 1999, accepted March 15, they prolong life in only a fraction of patients. Progression of atherosclerosis may lead to recurrent angina, myocardial infarction (), and death. Concurrent strategies to stabilize or reverse the atherosclerotic process are needed to improve long-term results. The 3-hydroxy-3methylglutaryl coenzyme A (HMG- CoA) reductase inhibitors cause substantial reductions in serum total and low density lipoprotein cholesterol (LDL-C) and result in arrest of progression or regression of atherosclerotic lesions in up to 77% of hypercholesterolemic patients with coronary artery disease over a two- to fouryear follow-up period (2 5). It is important to note that these agents have been shown to improve clinical outcomes in patients with coronary artery disease with average cholesterol values (6) and in patients without established
2 JACC Vol. 34, No. 1, 1999 July 1999: Flaker et al. Pravastatin and Cholesterol 107 Abbreviations and Acronyms CABG coronary artery bypass graft CARE Cholesterol and Recurrent Events trial CHD coronary heart disease CHF congestive heart failure CPK creatine phosphokinase HDL-C high density lipoprotein cholesterol HMG-CoA 3-hydroxy-3 methylglutaryl coenzyme A LDL-C low density lipoprotein cholesterol myocardial infarction PTCA percutaneous transluminal coronary angioplasty coronary artery disease with elevated (7) or borderline elevated LDL-C (8). Little long-term, controlled information is available on the effects of these agents on cardiovascular events in patients who have had revascularization procedures, particularly in patients with average serum cholesterol values. The Cholesterol and Recurrent Events (CARE) trial offered a unique opportunity to evaluate the effects of the HMG-CoA reductase inhibitor pravastatin in post- patients who had undergone coronary revascularization before revascularization and who had a total cholesterol 240 mg/dl (6.2 mmol/liter) and an LDL-C of 115 to 174 mg/dl (3.0 to 4.5 mmol/liter). In this analysis, we compared the five-year follow-up of 2,245 revascularized patients in the CARE study who were randomized to either pravastatin 40 mg/day or placebo. METHODS The design of the CARE trial (9), its baseline findings (10) and final results (6) have been described previously. The CARE was a multicenter, randomized, double blind, placebo-controlled trial designed to assess the efficacy of the HMG-CoA reductase inhibitor pravastatin in reducing fatal coronary heart disease (CHD) and nonfatal. Patients who survived an (3 to 20 months before randomization), had a plasma total cholesterol 240 mg/dl (6.2 mmol/liter), and LDL-C of 115 to 174 mg/dl (3.0 to 4.5 mmol/liter) were eligible for the trial. From December 1989 through December 1991, a total of 4,159 men and women between 21 and 75 years of age were randomized to the study from 80 centers in North America. Patients were randomized either to placebo or pravastatin 40 mg/day, designed to achieve an average reduction in LDL-C of approximately 30%, and an increase in high density lipoprotein cholesterol (HDL-C) of 5%. The median duration of follow-up was five years. Patients in the CARE study were not enrolled for at least six months after percutaneous transluminal coronary angioplasty (PTCA) and three months after coronary artery bypass graft (CABG) to ensure clinical stability. This analysis evaluates all patients who underwent coronary revascularization before randomization to pravastatin or placebo. All clinical cardiovascular end points were validated by hospital records. Coronary death, nonfatal and stroke were evaluated by committees blinded to treatment assignment. STATISTICAL ANALYSIS All analyses were performed on an intention-to-treat basis, and p values were two-sided. The comparibility of baseline characteristics in the two treatment groups was ascertained using standard normal tests for continuous variables and chi-square tests for categorical variables. All hypothesis testing and all risk reductions with their confidence intervals were assessed using the Cox proportional hazards model. Kaplan-Meier survival curves for the control and pravastatin groups were calculated (11). The relationship between treatment assignment and the primary end point in CARE was assessed using a Cox proportional hazards model using time to the primary end point as the dependent variable. Patients who had a primary end point were uncensored and removed from the analysis at the time of the occurrence of a primary end point. Patients without a primary end point were censored at the time of their last follow-up visit. The influence of on-treatment LDL-C was investigated in time-dependent Cox analyses with a weighted average of the patient s follow-up LDL-C values. The primary end point of the study was cardiovascular death or nonfatal. Multivariate models adjusted for the baseline variables of age, gender, smoking history, diabetes, hypertension and left ventricular ejection fraction. RESULTS A total of 2,245 patients had undergone coronary revascularization before randomization in the CARE trial. Included in this group were 1,154 patients who had undergone PTCA alone without a prior CABG. A total of 876 patients had undergone CABG without PTCA before randomization; an additional 215 patients had both PTCA and CABG before randomization, for a total of 1,091 patients with CABG. In 223 patients, PTCA occurred before the index ; in 220 patients CABG took place before the index. In the remaining patients, revascularization was performed between the index and randomization. At the time of randomization, there were differences between the 2,245 revascularized patients and the 1,914 nonrevascularized patients. Revascularized patients were more often male and white, and a higher fraction lived in the U.S. than in Canada. Revascularized patients were less often current smokers. They were less likely to have had a Q wave, had a lower peak creatine phosphokinase (CPK), had more often received thrombolysis, had a higher left ventricular ejection fraction and a lower Canadian Cardiovascular Classification compared with nonrevascularized patients. Differences in medications were also noted be-
3 108 Flaker et al. JACC Vol. 34, No. 1, 1999 Pravastatin and Cholesterol July 1999: Table 1. Baseline Characteristics of Revascularized and Nonrevascularized Patients CABG or PTCA No Revascularization PTCA Only All CABG n 2,245 1,914 1,154 1,091 Age (yr) NS Sex (%) Male Female Race (%) White NS Other Country US (%) NS Canada (%) Hypertension (%) NS Current smoker (%) Diabetes (%) NS type Q wave NS Peak CPK ( /dl) CHF NS Thrombolysis Canadian Class I II III IV Ejection fraction (%) History of stroke NS Medications Aspirin Beta-blocker Nitrate Calcium channel-blockers NS ACE inhibitors Diuretic agent NS Insulin NS Oral hypoglycemic agent NS NS Estrogen NS NS Plasma lipid cholesterol Total (mg/dl) NS NS LDL (mg/dl) NS NS HDL (mg/dl) NS Triglycerides (mg/dl) NS NS tween revascularized and nonrevascularized patients (Table 1). Differences also existed between the baseline characteristics of patients who had previously received PTCA exclusively and those who received CABG without and with PTCA (Table 1). Those patients who received PTCA only were younger, had a lower incidence of hypertension and diabetes but were more frequently current smokers compared with CABG patients. The PTCA-only patients had a lower incidence of congestive heart failure (CHF) and stroke, a higher peak CPK during the index but had a higher left ventricular ejection fraction. They had more frequently received thrombolysis, had a slightly higher HDL-C, and had a lower Canadian Cardiovascular Classification compared with CABG patients. Differences in medications received upon entry into the CARE study were also noted between PTCA and CABG patients (Table 1). There were no important differences in characteristics of subgroups based on treatment assignment. During the follow-up period, the mean total cholesterol, LDL-C, HDL-C, and triglyceride values did not change significantly in the revascularized patients treated with placebo. The average LDL-C in placebo-treated PTCA patients was mg/dl, and the average total cholesterol was mg/dl. The average LDL-C in placebo-treated CABG patients was mg/dl, and
4 JACC Vol. 34, No. 1, 1999 July 1999: Flaker et al. Pravastatin and Cholesterol 109 the average total cholesterol was mg/dl. Pravastatin resulted in marked reductions of LDL-C and total cholesterol in both PTCA and CABG patients. The average LDL-C in PTCA patients treated with pravastatin was mg/dl, and the average total cholesterol was mg/dl. The average LDL-C in CABG patients treated with pravastatin was mg/dl, and the average total cholesterol was mg/dl. Among the 2,245 patients who had undergone coronary revascularization before randomization, those assigned to pravastatin experienced fewer primary end points (CHD death or nonfatal ), fewer s (fatal and nonfatal) and fewer strokes (Table 2). The absolute reduction for CHD death or nonfatal, the prespecified primary end point of the CARE trial, was 4.1% (relative risk [RR] reduction 36%, 95% confidence interval [CI] 17 to 51, p 0.001). For recurrent (fatal or nonfatal) the absolute risk reduction was 3.3% (RR reduction 39%, 95% CI 16 to 55, p 0.002), for stroke it was 1.5% (RR reduction 39%, 95% CI 3 to 62, p 0.037), and for repeat revascularization it was 2.6% (RR reduction 18%, 95% CI 1 to 33%, p 0.068). The beneficial effects of pravastatin were striking among the 1,154 PTCA patients as well as the 1,091 CABG patients who had undergone revascularization before randomization. For PTCA patients, CHD death or nonfatal was reduced by 4.5% (RR reduction 39%, 95% CI 10 to 58%, p 0.011, Fig. 1). For recurrent (fatal or nonfatal) the absolute risk reduction was 4.0% (RR reduction 43%, 95% CI 13 to 63%, p 0.009, Fig. 2). The need for postrandomization revascularization was reduced with pravastatin in PTCA patients by 4.8% (RR reduction 22%, 95% CI 0 to 40%, p 0.05, Fig. 3). The absolute risk reduction for stroke was 2.6% (RR reduction 72%, 95% CI 31 to 89%, p 0.006, Fig. 4). Death from all causes occurred in 5.8% of the placebo-treated patients and 6.7% of the pravastatin patients; CHD death occurred in 2.9% of the placebo patients and 3.2% of the pravastatin-treated patients. In the 1,091 CABG patients, the primary end point (CHD death or nonfatal ) was reduced by 3.8% (RR reduction 33%, 95% CI 3 to 53%, p 0.034, Fig. 5). Death from CHD was reduced by 3.2% (RR reduction 44%, 95% CI 7 to 66, p 0.024). All-cause mortality was reduced by 4.4% (relative risk reduction 38%, 95% CI 9 to 58, p 0.014). There were trends for reductions in total (fatal and nonfatal), need for PTCA, and stroke and a trend toward an increase in repeat CABG in these CABG patients. The 1,914 patients who had not been revascularized experienced reductions in clinical events with pravastatin, but these reductions were not as striking as those who had been revascularized (Table 2). Nonsignificant reductions in CHD death or nonfatal (absolute risk reduction 1.6%, p 0.37), recurrent (absolute risk reduction 1.2%, p 0.39), and stroke (absolute risk reduction 0.7%, p 0.38) were noted. The need for revascularization was reduced in the pravastatin group by 7.1% (RR reduction 35%, 95% CI 19 to 48%, p 0.001). The tests for interaction for the effectiveness of pravastatin between the revascularized and nonrevascularized group were not significant. An on-treatment analysis was performed to determine the most desirable LDL-C values in revascularized patients. Patients who received pravastatin were divided into quintiles based on the average LDL-C from all follow-up values. The primary end point for PTCA patients in the lowest quintile (LDL-C 84 mg/dl) was not significantly different when compared to PTCA patients in the highest quintile (LDL-C 112 mg/dl). Similarly, the primary end point for CABG patients in the lowest quintile (LDL-C 82 mg/dl) was not statistically significant when compared with CABG patients in the highest quintile ( 114 mg/dl). The RR for the primary end point was not significantly different for PTCA and CABG patients in all quintiles, even when adjusted for differences in baseline variables; however, the side confidence intervals prevented a definite statistical conclusion. In summary, pravastatin reduced coronary heart death and nonfatal in patients who had undergone revascularization before randomization into CARE. Pravastatin reduced, prevented the need for repeat revascularization, and reduced stroke in PTCA-treated patients. In nonrevascularized patients, pravastatin reduced the need for subsequent PTCA or CABG. DISCUSSION The HMG-CoA reductase inhibitors have earned a pivotal place in the management of patients with hypercholesterolemia. Reductions in cardiovascular mortality and have been demonstrated in hypercholesterolemic patients with and without established coronary artery disease with some of these agents (6,12). The current analysis demonstrates the importance of this form of therapy in post- patients with average cholesterol values and whose coronary artery disease was deemed severe enough to warrant revascularization before enrollment in the trial. Pravastatin was well tolerated in this (6) and other trials (7). Recent studies have shown that lipid-lowering agents are infrequently used in patients undergoing revascularization following myocardial infarction. In the VANQWISH trial (13) only 17% of patients with a non-q-wave had an elevated cholesterol level. Only 13% of patients in this category received a lipid-lowering agent (13). Given the favorable results of HMG-CoA reductase inhibitor therapy in revascularized patients, this therapy should be considered for almost all patients after PTCA and CABG. Lipid therapy and PTCA. Previous studies have demonstrated the ineffectiveness of several HMG-CoA reductase inhibitors in preventing restenosis after PTCA (14,15). Following PTCA, injury to the vessel wall is deep and the vessel is expanded (16). A multifactorial inflammatory response occurs, with smooth muscle cells and neointima formation as the predominant cellular response (17,18).
5 110 Flaker et al. JACC Vol. 34, No. 1, 1999 Pravastatin and Cholesterol July 1999: Table 2. Cardiovascular End Points in Revascularized and Nonrevascularized Patients Any Revascularization (n 1,118) (n 1,127) Reduction (95% CI) CHD death/nonfatal % % 36 (17 to 51) CHD death % % 30 ( 3 to 53) 0.70 Nonfatal or fatal % % 39 (16 to 55) CABG % % 9 ( 26 to 34) PTCA % % 18 ( 6 to 37) Any revascularization % % 18 ( 1 to 33) Stroke % % 39 (3 to 62) Total mortality % % 22 ( 4 to 42) No Revascularization (n 960) (n 954) Reduction (95% CI) CHD death/nonfatal % % 11 ( 14 to 30) CHD death % % 8 ( 67 to 37) Nonfatal or fatal % % 12 ( 17 to 33) CABG % % 36 (15 to 51) PTCA % % 30 (4 to 49) Any revascularization % % 35 (19 to 48) Stroke % % 21 ( 34 to 53) Total mortality % % 6 ( 41 to 20) PTCA Patients (n 554) (n 600) Reduction (95% CI) CHD death/nonfatal % % 39 (10 to 58) CHD death % % 9 (102 to 82) Nonfatal or fatal % % 43 (13 to 63) CABG % % 32 ( 1 to 54) PTCA % % 13 ( 19 to 36) Any revascularization % % 22 (0 to 40) Stroke % 6 1.0% 72 (31 to 89) Total mortality % % 15 ( 83 to 28) CABG Patients (n 564) of Events (n 527) of Events Reduction (95% CI) CHD death/nonfatal % % 33 (3 to 53) CHD death % % 44 (7 to 66) Nonfatal or fatal % % 33 ( 5 to 57) CABG % % 59 ( 184 to.11) PTCA % % 34 ( 5 to 59) Any revascularization % % 14 ( 24 to 41) Stroke % % 9 ( 60 to 48) Total mortality % % 38 (9 to 58) 0.014
6 JACC Vol. 34, No. 1, 1999 July 1999: Flaker et al. Pravastatin and Cholesterol 111 Figure 1. Primary event rate in PTCA-treated patients on pravastatin or placebo. Figure 3. Revascularization in PTCA-treated patients on pravastatin or placebo. Angiographic trials have demonstrated restenosis in 30% to 60% of patients within six months (19,20). Because patients in the CARE study were enrolled at least six months after PTCA, the early problems with restenosis would not be addressed with this analysis. Instead, the reduction in events associated with pravastatin in PTCA patients observed in CARE was not an early but rather a late effect and likely due to alteration in the athersclerotic process. The current analysis is the first demonstration of long-term clinical benefit of cholesterol lowering in patients who have undergone PTCA. Lipid therapy and CABG. In CABG patients, LDL-C reduction has been shown to reduce atherosclerosis in bypass grafts and native vessels. In a substudy of the Cholesterol Lowering Athersclerosis Study (CLAS), 162 men with an average baseline LDL-C of 170 mg/dl received either colestipol and niacin or placebo. In the group receiving active therapy, the LDL-C value was reduced by 43% and new lesions were reduced in native vessels and bypass grafts (21). In the Post Coronary Artery Bypass Trial (22) patients with elevated LDL-C values (mean 155 mg/dl) were randomized to receive moderately aggressive lipid therapy, designed to reduce LDL-C to a goal of 130 to 140 mg/dl, or aggressive lipid therapy to reach a goal of 60 to 85 mg/dl. Patients in the moderately aggressive arm were treated with lovastatin and had LDL-C values of 132 to 136 mg/dl, similar to the baseline LDL-C value of 138 mg/dl in the current study. Patients in the aggressive arm received more intensive therapy and attained LDL-C values of 93 to 97 mg/dl. These patients were found to have reduced graft atherosclerosis compared with the patients who were treated with moderately aggressive therapy. In our pravastatin-treated patients, an on-treatment LDL-C of 98 mg/dl is similar to the aggressively treated arm in the post-cabg trial. In contrast to the post-cabg results, CARE demonstrated a reduction in hard coronary end points including CHD death and total mortality in CABG patients. The results in CARE were achieved with monotherapy using normal doses of pravastatin, 40 mg. The relationship between on-treatment LDL-C and event rates in CARE has been described elsewhere (23). The reduction in clinical events with pravastatin was especially striking in revascularized CARE patients. The PTCA patients and CABG patients treated with pravastatin had fewer primary end points (deaths due to coronary heart disease or nonfatal s). The PTCA patients in the pravastatin group had significantly fewer s, less repeat revascularizations, and fewer strokes. Nonrevascularized patients assigned to pravastatin had significantly fewer revascularization procedures but did not have significantly fewer primary end points or fewer s or strokes. The reason for this observation is unclear and may be due to Figure 2. Fatal or non-fatal in PTCA-treated patients on pravastatin or placebo. Figure 4. Stroke in PTCA-treated patients on pravastatin or placebo.
7 112 Flaker et al. JACC Vol. 34, No. 1, 1999 Pravastatin and Cholesterol July 1999: Figure 5. Primary event rate in CABG-treated patients on pravastatin or placebo. chance because the test for interactions between pravastatin treatment and prior revascularization was not significant. It is also possible that pravastatin is especially effective in more extensive forms of atherosclerosis that are severe enough to warrant some form of revascularization. Conclusions. In summary, pravastatin has been shown to reduce important clinical events in patients who had previously undergone coronary revascularization. The favorable effects became obvious over an extended period of time. This analysis of revascularized patients was part of the larger CARE cohort in which pravastatin was shown to reduce clinical events in post- patients with average cholesterol values. This is a limitation of the study, but until further information becomes available, it appears that HMG-CoA reductase inhibitors should be considered in most patients who have undergone coronary revascularization. Reprint requests and correspondence: Dr. Greg Flaker, University of Missouri Hospital and Clinics, Department of Cardiology, Room MC-501, One Hospital Drive, Columbia, Missouri greg_flaker@muccmail.hsc.missouri.edu. REFERENCES 1. American Heart Association; Heart and Stroke Statistical Update, Blankenhorn DH, Azen SP, Kramsch DM, et al., and the MARS Research Group. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119: MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre antiatheroma study (MAAS). Lancet 1994;334: Waters D, Higginson L, Gladstone P, et al., and the CCAIT study group. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89: Jukema JW, Bruschke AVG, vanboven AJ, et al., on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995;91: Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335: Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333: Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279: Sacks FM, Pfeffer MA, Moye LA, et al. The Cholesterol and Recurrent Events Trial: Rationale, design and baseline characteristics of secondary prevention trial of lowering serum cholesterol and myocardial infarction. Am J Cardiol 1991;68: Pfeffer MA, Sacks FM, Moye LA, et al., for the Cholesterol and Recurrent Events Clinical Trial Investigators. Cholesterol and Recurrent Events trial: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995;76:98C 106C. 11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. JAMA 1958;53: Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: Boden WE, O Rourke RA, Crawford MH, et al., for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338: Bertrand ME, McFadden EP, Fruchart J, et al., for the PREDICT Trial investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997;30: Weintraub WS, Boccuzzi SJ, Klein L, et al., and the Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331: Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiologic response to injury in a pig model. Circ Res 1985;57: Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990;1: Austin GE, Ratliff NB, Hollman J, Tabeil S, Phillips D. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after coronary angioplasty. J Am Coll Cardiol 1985;6: Holmes DR, Vlietstra R, Smith H, et al. Restenosis after coronary angioplasty (PTCA): a report from the PTCA registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77 81C. 20. Serruys PW, Luijten HE, Beatt KJ, et al. of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, and 3 months. Circulation 1988;77: Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined co-niacin therapy on coronary atherosclerosis and coronary artery bypass grafts. JAMA 1987;257: The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336: Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 1998;97:
Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationEffects of Statins on Restenosis After Coronary Stent Implantation
Angiology Volume 58, Number 1, 2007 55 Effects of Statins on Restenosis After Coronary Stent Implantation Hirotoshi Kamishirado, MD, *Teruo Inoue, MD, FACC,* Masashi Sakuma, MD, Tatsuhiro Tsuda, MD, Terumi
More informationAt what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
European Heart Journal (2001) 22, 919 925 doi:10.1053/euhj.2000.2484, available online at http://www.idealibrary.com on At what coronary risk level is it cost-effective to initiate cholesterol lowering
More informationThe clearly demonstrated benefits of cholesterol-lowering. Clinical Investigation and Reports
Clinical Investigation and Reports Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis The /Enalapril Coronary Atherosclerosis Trial (SCAT)
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationOutcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease
10 CLINICAL STUDIES JACC Vol. 31, No. 1 INTERVENTIONAL CARDIOLOGY Outcome of Coronary Bypass Surgery Versus Coronary Angioplasty in Diabetic Patients With Multivessel Coronary Artery Disease WILLIAM S.
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationAddendum to Clinical Review for NDA 22-512
Addendum to Clinical Review for DA 22-512 Drug: Sponsor: Indication: Division: Reviewers: dabigatran (Pradaxa) Boehringer Ingelheim Prevention of stroke and systemic embolism in atrial fibrillation Division
More informationThe Intensive Statin Therapy Myth
F o c u s Michael Shechter MD MA, Roy Beigel MD, Shlomi Matetzky MD, Dov Freimark MD and Pierre Chouraqui MD Heart Institute, Sheba Medical Center, Tel Hashomer, Israel Affiliated to Sackler Faculty of
More informationSteven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,
More informationStatins for Hyperlipidemia (High Cholesterol)
Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationWill The Coronary Calcium Score Affect the Decision To Treat With Statins?
Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 1995, by the Massachusetts Medical Society Volume 333 NOVEMBER 16, 1995 Number PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA JAMES SHEPHERD, M.D., STUART
More informationMany asymptomatic individuals
Facts, myths and misconceptions about LDL-C and HDL-C By Michael B. Clearfield, DO Many asymptomatic individuals will succumb to cardiovascular disease (CVD), which is the leading cause of death and loss
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors (Statins) Final Report September 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationMaking Sense of the New Statin guidelines. They are more than just lowering your cholesterol!
Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationManagement of Lipids in 2015: Just Give them a Statin?
Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES Niteesh K. Choudhry, MD, PhD Harvard Medical School Division of Pharmacoepidemiology and Pharmacoeconomics
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationThe return of myocardial ischemia after coronary artery
Occurrence and Risk Factors for Reintervention After Coronary Artery Bypass Grafting Joseph F. Sabik III, MD; Eugene H. Blackstone, MD; A. Marc Gillinov, MD; Nicholas G. Smedira, MD; Bruce W. Lytle, MD
More informationBMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: Trilipix (ABT-335) Name of Active Ingredient: choline salt of fenofibric acid Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationEffect of an Intervention to Increase Statin Use in Medicare Members Who Qualified for a Medication Therapy Management Program
RESEARCH Effect of an Intervention to Increase Statin Use in Medicare Members Karen M. Stockl, PharmD; Daniel Tjioe, PharmD; Sherry Gong, MS; Jenni Stroup, BA; Ann S. M. Harada, PhD, MPH; and Heidi C.
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationThe American Cancer Society Cancer Prevention Study I: 12-Year Followup
Chapter 3 The American Cancer Society Cancer Prevention Study I: 12-Year Followup of 1 Million Men and Women David M. Burns, Thomas G. Shanks, Won Choi, Michael J. Thun, Clark W. Heath, Jr., and Lawrence
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationJournal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.
Journal of the American College of Cardiology Vol. 38, No. 2, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01408-5 Prognostic
More informationAssociate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland
Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for
More informationACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc
ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc ABSTRACT Objective; In this study we looked at the demographic characteristics and the frequency of the various risk
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationGENERAL HEART DISEASE KNOW THE FACTS
GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationCardiovascular disease is the leading cause of morbidity
electronic health records Implementation of an Electronic Health Record with an Embedded Quality Improvement Program to Improve the Longitudinal Care of Outpatients with Coronary Artery Disease Allan G.
More informationProtocol. Cardiac Rehabilitation in the Outpatient Setting
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationRisk Factors for Fire Fighter Cardiovascular Disease
Risk Factors for Fire Fighter Cardiovascular Disease EXECUTIVE SUMMARY Prepared by: Jefferey L. Burgess, MD, MS, MPH Mel and Enid Zuckerman College of Public Health The University of Arizona The Fire Protection
More informationThe Canadian Association of Cardiac
Reinventing Cardiac Rehabilitation Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationCardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease
Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationLipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Amit Sachdeva, MD, a Christopher P. Cannon, MD, b Prakash C. Deedwania,
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationAntonio Colombo MD on behalf of the SECURITY Investigators
Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationCohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationPotential Clinical and Economic Impact of Statin Formulary Management
Potential Clinical and Economic Impact of Statin Formulary Management Karol E. Watson, MD Summary The evidence is clear that aggressive management of cardiac risk factors is beneficial and generally safe
More informationPerspectives on the Selection and Duration of Dual Antiplatelet Therapy
Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationSecondary Prevention and Rehabilitation
Secondary Prevention and Rehabilitation Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease Manohara P. J.
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
More informationA randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
More informationAssessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study
European Journal of Clinical Investigation (2007) 37, 925 932 DOI: 10.1111/j.1365-2362.2007.01888.x Blackwell Publishing Ltd Review Assessing risk of myocardial infarction and stroke: new data from the
More informationA Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs
A Patient s Guide to Primary and Secondary Prevention of PATIENT EDUCATION GUIDE What Is Cardiovascular Disease? Cardiovascular disease (CVD) is a broad term that covers any disease of the heart and circulatory
More informationFULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.
FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION NEW ENGLAND JOURNAL OF MEDICINE 2011; DOI: 10.1056/NEJMSA1107913 Niteesh K. Choudhry, MD, PhD, 1 Jerry Avorn, MD, 1 Robert J. Glynn,
More informationCardiovascular Disease and Diabetes Management of Chronic Coronary Disease
Cardiovascular Disease and Diabetes Management of Chronic Coronary Disease Donald E. Cutlip, MD Beth Israel Deaconess Medical Center Harvard Clinical Research Institute Harvard Medical School Diabetes
More informationHormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
More informationCardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
More informationEUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events
II European Action on Secondary and Primary Prevention through Intervention to Reduce Events Euro Heart Survey Programme European Society of Cardiology-ESC 1 2 Priorities of Coronary Heart Disease Prevention
More informationThe Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs
The Role of Insurance in Providing Access to Cardiac Care in Maryland Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs Heart Disease Heart Disease is the leading cause of death
More informationTips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD
Tips for surviving the analysis of survival data Philip Twumasi-Ankrah, PhD Big picture In medical research and many other areas of research, we often confront continuous, ordinal or dichotomous outcomes
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationClinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up
Hellenic J Cardiol 45: 379-383, 2004 Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up PETROS S. DARDAS, DIMITRIS
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationAntiaggreganti. STEMI : cosa c è di nuovo? Heartline 2015. Genova 13 14 Novembre 2015
Heartline 2015 Genova 13 14 Novembre 2015 STEMI : cosa c è di nuovo? Antiaggreganti Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia STEMI : cosa c è di nuovo?
More informationWhat is a Heart Attack? 1,2,3
S What is a Heart Attack? 1,2,3 Heart attacks, otherwise known as myocardial infarctions, are caused when the blood supply to a section of the heart is suddenly disrupted. Without the oxygen supplied by
More informationClinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013. Reference: NHSCB/A09/PS/b
Clinical Commissioning Policy Statement: Percutaneous mitral valve leaflet repair for mitral regurgitation April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy Statement: Percutaneous
More informationLEADERS: 5-Year Follow-up
LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS
More informationPerioperative Cardiac Evaluation
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
More information